Kosiborod, M. N., Esterline, R., Furtado, R. H. M., Oscarsson, J., Gasparyan, S. B., Koch, G. G., . . . Berwanger, O. (2021). Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol.
Style de citation ChicagoKosiborod, Mikhail N., et al. "Dapagliflozin in Patients With Cardiometabolic Risk Factors Hospitalised With COVID-19 (DARE-19): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." Lancet Diabetes Endocrinol 2021.
Style de citation MLAKosiborod, Mikhail N., et al. "Dapagliflozin in Patients With Cardiometabolic Risk Factors Hospitalised With COVID-19 (DARE-19): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." Lancet Diabetes Endocrinol 2021.